レベル別の英語ニュース

FDA Approves AstraZeneca's Baxfendy (Baxdrostat), the First-in-Class Aldosterone Synthase Inhibitor for Hard-to-Treat Hypertension

The U.S. Food and Drug Administration on May 18, 2026 granted full approval to AstraZeneca's once-daily oral tablet Baxfendy — generic name baxdrostat — making it the first aldosterone synthase inhibitor ever cleared anywhere in the world. The new mechanism selectively blocks the CYP11B2 enzyme that drives aldosterone synthesis without touching cortisol, and is indicated as add-on therapy for adults with uncontrolled or treatment-resistant hypertension. Approval rests on the 22,000-patient BaxHTN, BaxHTN-OL and BaxResist programme, in which 2 mg of baxdrostat layered on top of standard care lowered seated systolic blood pressure by an additional 9.8 mmHg at twelve weeks versus placebo.